Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease

A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from metastatic melanoma, according to interim analyses of a Phase I/Ib trial led by researchers at The University of Texas MD Anderson Cancer Center.

Dual Immunotherapy Regimen Delays Cancer Progression in Patients with Advanced Melanoma

A treatment regimen for patients with advanced melanoma that combines the immunotherapy agents relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) delayed time to cancer progression significantly more than nivolumab alone, according to results of a study to be presented June 6 at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.

Immunotherapy Before Surgery Could Advance Care of an Aggressive Form of Skin Cancer

In what is believed to be a first-of-its-kind study to evaluate the safety of a type of immunotherapy before surgery in patients with an aggressive form of skin cancer, researchers report that the treatment eliminated pathologic evidence of cancer in nearly half of the study participants undergoing surgery. In patients whose tumors respond, this treatment approach offers the potential to reduce the extent of surgery and may also slow or eliminate tumor relapses that often occur after surgery.